Lantern Pharma (NASDAQ: LTRN), an AI-driven precision oncology company, has launched ZetaOmics, the computational biology module of its multi-agentic AI co-scientist platform, withZeta.ai. The new module introduces an autonomous “Computational Biologist” agent designed to perform end-to-end bioinformatics and multi-omic analysis across cancer types. Initially available through an early-access program for select academic, industry and company collaborators, the platform automates complex research workflows while embedding domain-specific intelligence to improve analytical rigor and reproducibility.
According to the company, ZetaOmics combines 14 specialized tools that can autonomously design, execute and validate biological analyses, detect potential flaws in experimental design and generate publication-quality results with a complete audit trail. This capability is expected to significantly reduce the time and effort required for bioinformatics tasks, enabling researchers to focus on interpreting results and advancing their studies.
The launch of ZetaOmics expands withZeta.ai’s commercial opportunity beyond rare cancers by targeting academic medical centers, biotechnology and pharmaceutical companies, cancer centers and contract research organizations through subscription-based offerings and strategic collaborations. This move positions Lantern to generate a new revenue stream from its AI platform, which is now commercially available as a subscription-based research platform for the global biomedical and drug development community.
Lantern Pharma’s clinical pipeline includes LP-184 (acylfulvene), LP-284 (a TC-NER targeting compound in hematologic and solid tumors), and LP-300 (cisplatin/ethacraplatin analog), which is being evaluated in the HARMONIC Phase 2 trial in never-smoker patients with relapsed advanced lung adenocarcinoma following TKI treatment. LP-184 is also being developed for pediatric CNS cancers through Starlight Therapeutics, Lantern’s wholly owned CNS-focused subsidiary.
The company operates an AI Center of Excellence in Bengaluru, India and is headquartered in Dallas, Texas. For more information on the full press release, visit https://ibn.fm/9sIIl. Updates on Lantern Pharma are available in the company’s newsroom at https://ibn.fm/LTRN.
